Pharmaceutical care for a patient with empagliflozin-induced euglycemic diabetic ketoacidosis
- VernacularTitle:恩格列净致非高血糖性糖尿病酮症酸中毒患者的药学监护
- Author:
Lili YANG
1
,
2
;
Qi LI
3
;
Hui WANG
2
,
4
;
Ruilong GAO
5
;
Min MAO
2
Author Information
1. Dept. of Clinical Pharmacy，Zibo Central Hospital，Shandong Zibo 255036，China
2. Dept. of Pharmacy，China-Japan Friendship Hospital，Beijing 100029，China
3. Dept. of Nephrology，Zibo Central Hospital，Shandong Zibo 255036，China
4. Dept. of Pharmacy，Yutian County Hospital of Traditional Chinese Medicine of Hebei Province，Hebei Tangshan 064100，China
5. Dept. of Cardiology，China-Japan Friendship Hospital，Beijing 100029，China
- Publication Type:Journal Article
- Keywords:
empagliflozin;
euglycemic diabetic ketoacidosis;
limb-girdle muscular dystrophy;
type 2 diabetes mellitus;
sodium-
- From:
China Pharmacy
2025;36(2):214-218
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide a reference for the pharmaceutical care of a patient with type 2 diabetes mellitus （T2DM） and limb-girdle muscular dystrophy （LGMD） who developed euglycemic diabetic ketoacidosis （euDKA） after taking empagliflozin. METHODS Clinical pharmacists provided pharmaceutical care for a patient with T2DM and LGMD who developed euDKA after taking empagliflozin. According to the patient’s recent use of medications and his conditions， clinical pharmacists assessed the correlation between euDKA and empagliflozin as “very likely”. As to euDKA， clinical pharmacists suggested discontinuing empagliflozin and metformin， and giving intravenous infusion of 10% Glucose injection instead of 5% Glucose injection for fluid resuscitation. Clinical pharmacists monitored the patient’s laboratory indicators such as arterial blood gas analysis， blood/urine ketones and electrolytes. They assisted physicians to decide when to stop intravenous supplements of liquid and insulin. Clinical pharmacists also assisted physicians to adjust the antidiabetic drugs and educated the patient to avoid empagliflozin or other sodium- glucose linked transporter 2 inhibitors （SGLT2i）. RESULTS Physicians adopted the suggestions of clinical pharmacists. After treatment， the patient’s condition improved， and he was allowed to be discharged with medication. CONCLUSIONS euDKA is a relatively rare and serious adverse reaction associated with SGLT2i， and the patients with LGMD are susceptible to euDKA. Clinical pharmacists assist physicians in developing personalized medication plans by evaluating the association between euDKA and empagliflozin， adjusting medication regimens，conducting pharmaceutical monitoring，and other pharmaceutical services. Meanwhile， they provide medication education to patients to ensure their medication safety.
